Pharmaceutical industry [electronic resource] : innovation and developments / David A. Mancuso and Isobel M. Grenada, editors.

Contributor(s): Mancuso, David A | Grenada, Isobel M | ProQuest (Firm)Material type: TextTextSeries: Business issues, competition and entrepreneurship series | Pharmacology-research, safety testing, and regulation seriesPublication details: Hauppauge, N.Y. : Nova Science, c2011Description: ix, 182 p. : illISBN: 9781621004394 (electronic bk.)Subject(s): Drug development | Pharmaceutical industry | Drugs -- Law and legislationGenre/Form: Electronic books.DDC classification: 615/.19 LOC classification: RM301.25 | .P428 2011Online resources: Click to View
Contents:
Authorized generic pharmaceuticals : effects on innovation / John R. Thomas -- Authorized generics : an interim report / FTC -- Remarks of J. Thomas Rosch, Commissioner, Federal Trade Commission, before the World Generic Medicine Congress, hearing on "pay-for-delay settlements, authorized generics, and follow-on biologies : thoughts on the how competition law can best protect consumer welfare in the pharmaceutical context" -- Federal R&D, drug discovery, and pricing : insights from the NIH-university-industry relationship / Wendy H. Schacht -- Pharmaceutical R&D and the evolving market for prescription drugs / CBO -- Federal taxation of the drug industry and its effects on new drug development / Gary Guenther -- Pharmaceutical patent litigation settlements : implications for competition and innovation / John R. Thomas -- FDA's authority to regulate drug compounding : a legal analysis / Jennifer Staman -- Promotional spending for prescription drugs / CBO.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Includes bibliographical references and index.

Authorized generic pharmaceuticals : effects on innovation / John R. Thomas -- Authorized generics : an interim report / FTC -- Remarks of J. Thomas Rosch, Commissioner, Federal Trade Commission, before the World Generic Medicine Congress, hearing on "pay-for-delay settlements, authorized generics, and follow-on biologies : thoughts on the how competition law can best protect consumer welfare in the pharmaceutical context" -- Federal R&D, drug discovery, and pricing : insights from the NIH-university-industry relationship / Wendy H. Schacht -- Pharmaceutical R&D and the evolving market for prescription drugs / CBO -- Federal taxation of the drug industry and its effects on new drug development / Gary Guenther -- Pharmaceutical patent litigation settlements : implications for competition and innovation / John R. Thomas -- FDA's authority to regulate drug compounding : a legal analysis / Jennifer Staman -- Promotional spending for prescription drugs / CBO.

Electronic reproduction. Ann Arbor, MI : ProQuest, 2015. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries.

There are no comments on this title.

to post a comment.